

SEMINARS IN THROMBOSIS AND HEMOSTASIS – VOLUME 14 INDEX

AUTHOR INDEX

Andrew M, 28	Dol F, 18	Hirsh J, 116	Samama MM, 293, 363
Austin M, 137	Dupouy D, 18	Hoak JC, 202	Scru AM, 266
Aviram M, 258	Edwards EH, 189	Hornstra G, 59	Schaefer EJ, 143
Badimon JJ, 50	Edwards RL, 88	Juhan-Vague I, 180	Schmidt B, 28
Badimon L, 50	Eskin SG, 170	Kelley JL, 189	Schonfeld G, 184
Bastida E, 66	Esmon CT, 210	Leaf A, 290	Schwartz CJ, 189
Berliner JA, 206	Esmon NL, 210	Levine MN, 116	Sie P, 18
Bick RL, 133, 222, 293, 299, 363	Feinstein DI, 351	Lisiewicz J, 339	Sprague EA, 189
Black PL, 79	Fenton JW, 234	Loskutoff DJ, 100	Spector AA, 196
Boneu B, 18	Fogelman AM, 206	McIntire LV, 170	Talmadge JE, 79
Booyse FM, 175	Fuster V, 50	McNamara JR, 143	Territo M, 206
Bradley WA, 165, 175, 253	Gabaig AM, 18	Mitropoulos KA, 246	Thomas DP, 1
Brook JG, 258	Genest Jr. J, 149	Murano G, 133, 222, 293, 363	Tracy PB, 227
Bruce R, 175	Gianturco SH, 165, 175, 253	Navab M, 206	Turpie AGG, 41
Buchanan MR, 33	Goodnight Jr. SH, 285	Ofosu FA, 9	Valente AJ, 189
Cadroy Y, 18	Gray E, 9	Ordovas JM, 143	Van Lenten BJ, 206
Caranobe C, 18	Grossman BA, 241	Owen J, 241	Vega GL, 149
Chesbro J, 50	Grundy SM, 149	Palmer RH, 241	Walker FJ, 216
Collen D, 95, 180	Gurewich V, 110	Rickles FR, 88, 126	Wenzel E, 293, 363
Connor WE, 271	Hancock WW, 88, 126		Zacharski LR, 88
D'Amore PA, 73			

CUMULATIVE TABLE OF CONTENTS

Number 1

THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC, AND FIBRINOLYTIC DRUGS: A MECHANIC POINT OF VIEW

Eva Bastida, Ph.D., Michael R. Buchanan, Ph.D., and Frederick A. Ofosu, Ph.D.

Overview of Venous Thrombogenesis, Duncan P. Thomas, 1
Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties, Frederick A. Ofosu and Elaine Gray, 9
Pharmacokinetic Studies of Standard Unfractionated Heparin and Low Molecular Weight Heparins in the Rabbit, Bernard Boneu, Claudine Caranobe, Yves Cadroy, Frederique Dol, Anne-Marie Gabaig, Dominique Dupouy, and Pierre Sie, 18
Use of Heparin in Newborn Infants, Maureen Andrew and Barbara Schmidt, 28
Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds, Michael R. Buchanan, 33
Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism, Alexander G. G. Turpie, 41
Prevention of Thromboembolism Induced by Prosthetic Heart Valves, Valentin Fuster, Lina Badimon, Juan J. Badimon, and James Chesebro, 50
Effect of Dietary Lipids on Arterial Thrombus Formation: Rationale for the Support of Drug Therapy by Diet, Gerard Hornstra, 59

The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis, Eva Bastida, 66
Antiangiogenesis as a Strategy for Antimetastasis, Patricia A. D'Amore, 73
Immunotherapy of Metastatic Disease, James E. Talmadge and Paul L. Black, 79
Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulant and/or Antiplatelet Drugs in Cancer Treatment, Frederick R. Rickles, Wayne W. Hancock, Richard L. Edwards, and Leo R. Zacharski, 88
Potential Approaches for Therapeutic Intervention of Thrombosis by Fibrinolytic Agents, Desire Collen, 95
Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy, David J. Loskutoff, 100
Pro-Urokinase: Physicochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of Action, Victor Gurewich, 110
Clinical Use of Low Molecular Weight Heparins and Heparinoids, Mark N. Levine and Jack Hirsh, 116
Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions, Frederick R. Rickles and Wayne W. Hancock, 126
Abstracts of Current Literature, Genesio Murano and Rodger L. Bick, 133

SEMINARS IN THROMBOSIS AND HEMOSTASIS – VOLUME 14 INDEX

AUTHOR INDEX

Andrew M, 28	Dol F, 18	Hirsh J, 116	Samama MM, 293, 363
Austin M, 137	Dupouy D, 18	Hoak JC, 202	Scru AM, 266
Aviram M, 258	Edwards EH, 189	Hornstra G, 59	Schaefer EJ, 143
Badimon JJ, 50	Edwards RL, 88	Juhan-Vague I, 180	Schmidt B, 28
Badimon L, 50	Eskin SG, 170	Kelley JL, 189	Schonfeld G, 184
Bastida E, 66	Esmon CT, 210	Leaf A, 290	Schwartz CJ, 189
Berliner JA, 206	Esmon NL, 210	Levine MN, 116	Sie P, 18
Bick RL, 133, 222, 293, 299, 363	Feinstein DI, 351	Lisiewicz J, 339	Sprague EA, 189
Black PL, 79	Fenton JW, 234	Loskutoff DJ, 100	Spector AA, 196
Boneu B, 18	Fogelman AM, 206	McIntire LV, 170	Talmadge JE, 79
Booyse FM, 175	Fuster V, 50	McNamara JR, 143	Territo M, 206
Bradley WA, 165, 175, 253	Gabaig AM, 18	Mitropoulos KA, 246	Thomas DP, 1
Brook JG, 258	Genest Jr. J, 149	Murano G, 133, 222, 293, 363	Tracy PB, 227
Bruce R, 175	Gianturco SH, 165, 175, 253	Navab M, 206	Turpie AGG, 41
Buchanan MR, 33	Goodnight Jr. SH, 285	Ofosu FA, 9	Valente AJ, 189
Cadroy Y, 18	Gray E, 9	Ordovs JM, 143	Van Lenten BJ, 206
Caranobe C, 18	Grossman BA, 241	Owen J, 241	Vega GL, 149
Chesbro J, 50	Grundy SM, 149	Palmer RH, 241	Walker FJ, 216
Collen D, 95, 180	Gurewich V, 110	Rickles FR, 88, 126	Wenzel E, 293, 363
Connor WE, 271	Hancock WW, 88, 126		Zacharski LR, 88
D'Amore PA, 73			

CUMULATIVE TABLE OF CONTENTS

Number 1

THE RATIONALE FOR THE DEVELOPMENT OF ANTITHROMBOTIC, ANTIMETASTATIC, AND FIBRINOLYTIC DRUGS: A MECHANIC POINT OF VIEW

Eva Bastida, Ph.D., Michael R. Buchanan, Ph.D., and Frederick A. Ofosu, Ph.D.

Overview of Venous Thrombogenesis, Duncan P. Thomas, 1
Mechanisms of Action of Heparin: Applications to the Development of Derivatives of Heparin and Heparinoids with Antithrombotic Properties, Frederick A. Ofosu and Elaine Gray, 9
Pharmacokinetic Studies of Standard Unfractionated Heparin and Low Molecular Weight Heparins in the Rabbit, Bernard Boneu, Claudine Caranobe, Yves Cadroy, Frederique Dol, Anne-Marie Gabaig, Dominique Dupouy, and Pierre Sie, 18
Use of Heparin in Newborn Infants, Maureen Andrew and Barbara Schmidt, 28
Mechanisms of Pathogenesis of Arterial Thrombosis: Potential Sites of Inhibition by Therapeutic Compounds, Michael R. Buchanan, 33
Clinical Studies: Evidence for Intervention with Specific Antiplatelet Drugs in Arterial Thromboembolism, Alexander G. G. Turpie, 41
Prevention of Thromboembolism Induced by Prosthetic Heart Valves, Valentin Fuster, Lina Badimon, Juan J. Badimon, and James Chesebro, 50
Effect of Dietary Lipids on Arterial Thrombus Formation: Rationale for the Support of Drug Therapy by Diet, Gerard Hornstra, 59

The Metastatic Cascade: Potential Approaches for the Inhibition of Metastasis, Eva Bastida, 66
Antiangiogenesis as a Strategy for Antimetastasis, Patricia A. D'Amore, 73
Immunotherapy of Metastatic Disease, James E. Talmadge and Paul L. Black, 79
Antimetastatic Agents. I. Role of Cellular Procoagulants in the Pathogenesis of Fibrin Deposition in Cancer and the Use of Anticoagulant and/or Antiplatelet Drugs in Cancer Treatment, Frederick R. Rickles, Wayne W. Hancock, Richard L. Edwards, and Leo R. Zacharski, 88
Potential Approaches for Therapeutic Intervention of Thrombosis by Fibrinolytic Agents, Desire Collen, 95
Type 1 Plasminogen Activator Inhibitor and Its Potential Influence on Thrombolytic Therapy, David J. Loskutoff, 100
Pro-Urokinase: Physicochemical Properties and Promotion of Its Fibrinolytic Activity by Urokinase and by Tissue Plasminogen Activator with which It Has a Complementary Mechanism of Action, Victor Gurewich, 110
Clinical Use of Low Molecular Weight Heparins and Heparinoids, Mark N. Levine and Jack Hirsh, 116
Antimetastatic Agents. II. Summary of the Interactions of Tumor Cells with Blood Coagulation Factors, Platelets, Fibrinolytic Factors, and Inflammatory Cells and Their Soluble Mediators: Potential for Therapeutic Interventions, Frederick R. Rickles and Wayne W. Hancock, 126
Abstracts of Current Literature, Genesio Murano and Rodger L. Bick, 133

Number 2

**HYPERTRIGLYCERIDEMIA, ARTERIOSCLEROSIS,
AND THROMBOSIS: I**

Sandra H. Gianturco, Ph.D. and Momtaz K. Wassef, Ph.D.

Epidemiologic Associations Between Hypertriglyceridemia and Coronary Heart Disease, Melissa Austin, 137**Clinical Significance of Hypertriglyceridemia**, Ernst J. Schaefer, Judith R. McNamara, Jacques Genest, Jr., and Jose M. Ordovas, 143**Hypertriglyceridemia: Causes and Relation to Coronary Heart Disease**, Scott M. Grundy and Gloria Lena Vega, 149**Lipoprotein-Mediated Cellular Mechanisms for Atherogenesis in Hypertriglyceridemia**, Sandra H. Gianturco and William A. Bradley, 165**Hemodynamic Effects on Atherosclerosis and Thrombosis**, Suzanne G. Eskin and Larry V. McIntire, 170**Normal but Not Hypertriglyceridemic Very Low-Density Lipoprotein Induces Rapid Release of Tissue Plasminogen Activator from Cultured Human Umbilical Vein Endothelial Cells**, F. M. Booysse, R. Bruce, S. H. Gianturco, and W. A. Bradley, 175**Fibrinolysis and Atherosclerosis**, D. Collen and I. Juhan-Vague, 180**Hypertriglyceridemia in Noninsulin Dependent Diabetes Mellitus**, Gustav Schonfeld, 184**Thrombosis and the Development of Atherosclerosis: Rokitansky Revisited**, Colin J. Schwartz, Anthony J. Valente, Jim L. Kelley, Eugene A. Sprague, and Ellen H. Edwards, 189**Lipid and Lipoprotein Effects on Endothelial Eicosanoid Formation**, Arthur A. Spector, 196**Platelets and Atherosclerosis**, John C. Hoak, 202**Lipoprotein Receptors and Endothelial Cells**, Alan M. Fogelman, Judith A. Berliner, Brian J. Van Lenten, Mahamad Navab, and Mary Territo, 206**Protein C and the Endothelium**, Naomi L. Esmon and Charles T. Esmon, 210**Interactions of Protein S With Membranes**, Frederick J. Walker, 216**Abstracts of Current Literature**, Genesio Murano and Rodger L. Bick, 222

Number 3

**HYPERTRIGLYCERIDEMIA, ARTERIOSCLEROSIS,
AND THROMBOSIS: II**

Sandra H. Gianturco, Ph.D. and Momtaz K. Wassef, Ph.D.

Regulation of Thrombin Generation at Cell Surfaces, Paula B. Tracy, 227**Regulation of Thrombin Generation and Functions**, John W. Fenton II, 234**Hyperlipidemia and *in vivo* Hemostatic System Activation**, John Owen, Betty A. Grossman, and Robert H. Palmer, 241**Hypercoagulability and Factor VII in Hypertriglyceridemia**, K. A. Mitropoulos, 246**Vitamin K-Dependent Proteins Bind to Very Low-Density Lipoproteins**, William A. Bradley and Sandra H. Gianturco, 253**Platelet Lipoprotein Interactions**, J. Gerald Brook and M. Aviram, 258**Lipoprotein(a): A Genetically Determined Lipoprotein Containing a Glycoprotein of the Plasminogen Family**, Angelo M. Scuani, 266**Effects of Omega-3 Fatty Acids in Hypertriglyceridemic States**, William E. Connor, 271**Effects of Dietary Fish Oil and Omega-3 Fatty Acids on Platelets and Blood Vessels**, Scott H. Goodnight, Jr., 285**Effects of n-3 Fatty Acids on Reocclusion After Angioplasty**, Alexander Leaf, 290**Abstracts of Current Literature**, Rodger L. Bick, Genesio Murano, Meyer M. Samama, and Ernst Wenzel, 293

Number 4

DISSEMINATED INTRAVASCULAR COAGULATION: I

Rodger L. Bick, M.D., F.A.C.P.

Disseminated Intravascular Coagulation and Related Syndromes, Rodger L. Bick, 299**Disseminated Intravascular Coagulation in Acute Leukemia**, Jerzy Lisiewicz, 339**Treatment of Disseminated Intravascular Coagulation**, Donald I. Feinstein, 351**Abstracts of Current Literature**, Rodger L. Bick, Genesio Murano, Meyer M. Samama, and Ernst Wenzel, 363